“秋收冬藏”后，创新药行情2026年如何走？

Core Insights - The innovative drug sector is experiencing a significant revaluation, with a strong rebound in 2025 driven by explosive growth in global BD transactions, validating the quality of domestic R&D in China [2][3] - The market narrative is shifting from broad valuation revaluation to a focus on fundamental performance, emphasizing the importance of clinical data, sales reports, and the quality of BD transactions in determining company value [2] - Investment opportunities in the pharmaceutical sector are expanding, particularly in underappreciated segments with high potential, driven by domestic demand recovery and industry upgrades [3] Group 1: Investment Opportunities in Innovative Drugs - The innovative drug sector is expected to see continued investment returns starting in 2026, as R&D pipelines advance and commercial sales materialize [2][3] - Major innovative drug companies are now considered relatively cost-effective, with the market having corrected previously excessive valuations [2] - The focus will be on companies that can successfully translate scientific innovations into commercial outcomes, as these will be the future winners in the sector [2] Group 2: Investment Strategies - Investment strategies include deep research to select high-growth sub-sectors and individual stocks, with a focus on long-term holding and concentrated positions [4][5] - The selection process emphasizes high-growth industries, with a focus on identifying stocks that can leverage industry trends and maximize value [4] - A balanced portfolio approach is recommended, incorporating "turnaround" companies, "value" stocks, and "growth" stocks to optimize returns and manage risk [6] Group 3: Impact of AI on the Pharmaceutical Industry - AI is transforming the medical field, evolving from an auxiliary tool to a core component of medical services, with significant investment opportunities in platform companies that can leverage AI for revenue generation [7][8] - The application of AI in drug development and patient interaction is accelerating, with potential for creating a commercial ecosystem around AI in healthcare [7][8] - Long-term investment in AI-driven healthcare solutions is encouraged, focusing on companies that demonstrate real value creation and technological breakthroughs [8]